Trial Profile

A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo- and Active-Controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mixed amfetamine salts (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Therapeutic Use
Sponsors Shire

Most Recent Events

01 Apr 2019 Results evaluating the duration of efficacy, safety, and tolerability of SHP465 mixed amphetamine salts extended-release versus placebo and immediate-release MAS in adolescents with attention-deficit/hyperactivity disorder (ADHD).published in the Postgraduate Medicine
20 Jun 2017 Results published in the Shire Media Release
15 Feb 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com